Pitching Your Company? You Better Bring More Than Data to An Anecdote Fight.

There's a phone call that often decides whether your next round attracts investor interest, and you don't get to be on it.

It's the call your prospective investor makes to two or three community specialists they trust, one in Cleveland, one in LA, and one in Houston. If those three have doubts about whether your product is meaningfully better or actually fits their practice, the deal dies quietly. You'll get a polite pass and a vague reason. You'll never know it was Cleveland, LA, and Houston.

I've watched a version of this play out for almost 40 years. It started in my first week as Marketing Research Director at a division of Becton Dickinson.

My predecessor was presenting the results of a survey of about a hundred customers, all responding to a new product idea we were considering. The data was clear. The recommendation was reasonable.

When he finished, the VP of Sales spoke up.

"I don't know," he said. "I was down in Mobile last week and I ran this by Dr. Billy Bob Jones. He thought it was a bad idea. Dr. Johnny Ray down in Houston didn't like it either."

That was the end of the discussion. A hundred customers just got overruled by two.

Sitting there, I realized something I've carried ever since: anecdotes often beat numbers in a room full of executives, and they're going to keep doing it whether I like it or not.

Many people, when they see that happen, dig in on the data. Build better decks. Add more slides. Try to make the numbers louder.

I decided to do the opposite. If anecdotes were the currency of executive decision-making, I was going to have better anecdotes than the Sales VP. Not more of them, better ones. Which meant knowing the customers better than he did.

Over the next three months I did more than a hundred face-to-face interviews with physicians and lab directors in their offices, hospitals, and labs. The travel bills got me in trouble with my boss and our controller — harder to defend on a spreadsheet than a survey. We kept running surveys and conjoint analyses for any decision with real money behind it. But the interviews gave me something the surveys couldn't: named customer voices I could bring into a room. When the Sales VP brought a Billy Bob Jones, I had three that were sharper, more recent, and from customers whose judgment he couldn't dismiss. He read the room and adjusted.

That combination became the discipline I ran for the rest of my time at BD, evaluating every new product, licensing opportunity, and acquisition for the division. I built an early version of what we now call the RAMPx model to handle the quantitative side; the interviews gave me the color behind the scores. The products and deals that came out of that work are now a more than $2 billion business. The RAMPx model has developed much more fully in the almost forty years since. The dynamics that drive new product adoption haven’t.

VCs and strategics make investment decisions the way that division president made product development and licensing decisions. They read your deck, study your data, then pick up the phone. And often they don't call your KOLs. KOLs are known quantities, everyone looking at your deal has already spoken to them, and their support is priced into your valuation. The calls that often move decisions go to community physicians, the ones who will actually be prescribing your product between patients on a Tuesday morning. If those docs push back, the anecdotes travel back to the partner meeting exactly the way Billy Bob Jones traveled back to our division president. A hundred data points can still lose to two phone calls.

We saw this recently on a project for a VC evaluating a small clinical-stage company. On paper the story was clean — Phase 2 data showing positive benefit, credentialed KOLs on the SAB, a reasonable regulatory path. A VC evaluating the opportunity had us conduct in-depth interviews with a couple of payers and community-based specialists in addition to running the results through 15 specialists using our RAMPx model. The model output quantified the opportunity, the strength of the new product’s value proposition and the probability of commercial success.

The consistency between what the model showed with what the community specialists said about the dosing schedule presented a powerful argument to the VC. They wouldn't prescribe the new product as designed because it didn't fit easily in how they actually managed these patients and the incremental clinical benefit wasn’t sufficient to overcome that practice friction. The model showed those weren't outliers; the concern was structural. Without the model, the anecdotes were easy to dismiss. With the anecdotes, the model output was solidified and highly convincing.

To the VC and his team, this was a funding no-go. Sharing the findings with the team, the company adapted their clinical trial plans around a new dosing schedule. We're re-running RAMPx now, and the probability of the round closing is high.

None of this is to say anecdotes should beat numbers. You need both. The data earns you the meeting; the stories decide what happens in it. The sooner CEOs understand that, the sooner they stop losing rounds they never realized were slipping.

If you're raising for a product that will one day sit on a physician's shelf, you need to understand how it will fit into real clinical practice before the person doing diligence on you starts asking. Not just what your KOLs think, but what the community physician in an office park in Toledo is going to say about the product when no one from your company is in the room.

A solid investment story isn't built on spreadsheets alone. The data has to hold up when it meets the questions surrounding adoption. The strongest companies know what that physician in Toledo is going to say before the investor ever makes the call.